Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with concurrent platinum-based chemoradiation in unresectable stage III NSCLC
jRCT2080223897Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab + standard-of-care chemoradiotherapy with Placebo + standard-of-care chemoradiotherapy (2 arms). Primary endpoint: Progression-free survival. Started May 2018; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080223897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223897.